Dividend Power Score
A single, comprehensive score designed to measure the true strength of a company’s dividend.
This score combines three essential pillars of dividend quality:
Consistency – Measures how reliable the dividend has been over time, focusing on payment history, stability, and the absence of cuts or suspensions.
Payability – Assesses the company’s financial ability to sustain its dividend, taking into account cash flow, earnings coverage, balance sheet strength, and overall financial health.
Growth – Evaluates the long-term growth of both the dividend and the company’s share price, highlighting businesses that consistently increase payouts while creating shareholder value.
Higher scores identify companies that have historically delivered dependable income alongside sustained dividend growth and long-term capital appreciation.
Company Overview
Senseonics Holdings, Inc. is a medical technology company operating in the diabetes management and implantable medical device industries. The company develops and commercializes long-term continuous glucose monitoring (CGM) systems designed to help people with diabetes and their healthcare providers manage blood glucose levels more effectively. Senseonics’ core focus is implantable CGM technology, which differentiates it from competitors that primarily offer transcutaneous, short-duration sensors.
The company’s primary product line is the Eversense CGM System, including the Eversense E3 system, which offers extended sensor wear compared to traditional CGMs. Revenue is primarily generated through sales of CGM systems, including implantable sensors, external transmitters, and related consumables. Senseonics primarily serves insulin-dependent diabetes patients, endocrinologists, and healthcare systems. The company was founded in 1996 and evolved from a diagnostics-focused business into a pure-play implantable CGM company, culminating in U.S. regulatory approvals and commercial launches in the late 2010s and early 2020s.
Business Operations
Senseonics operates through a single reportable business focused on the development and commercialization of implantable CGM technology. Its flagship Eversense CGM System consists of an implantable sensor, a removable external transmitter, and a mobile application, with the implant procedure performed by trained healthcare professionals. The company generates revenue through product sales, distribution arrangements, and collaborative agreements related to CGM commercialization.
Commercial operations are supported through strategic partnerships rather than a fully internal global sales infrastructure. Notably, Senseonics relies on Ascensia Diabetes Care Holdings AG as its primary global commercial partner for sales, marketing, and distribution of Eversense systems in the United States, Europe, and other international markets. Senseonics retains responsibility for research and development, regulatory activities, and manufacturing of its implantable sensors.
Strategic Position & Investments
Senseonics’ strategic direction centers on advancing long-duration implantable CGM technology to improve patient convenience, adherence, and clinical outcomes. Growth initiatives include extending sensor longevity, enhancing accuracy, and expanding regulatory approvals for broader patient populations. The approval of the Eversense E3 system, with a sensor life of up to six months, represents a key milestone aligned with this strategy.
The company has made targeted investments in research and development rather than pursuing large-scale acquisitions. Its most significant strategic relationship is with Ascensia Diabetes Care Holdings AG, which included equity investments and long-term commercialization agreements. Senseonics is also developing next-generation CGM platforms, including sensors with longer wear duration and reduced calibration requirements, positioning the company within emerging trends in minimally invasive and patient-centric diabetes technologies.
Geographic Footprint
Senseonics is headquartered in Germantown, Maryland, United States, and operates primarily in North America and Europe. Its commercial reach extends internationally through distribution and commercialization partnerships rather than wholly owned foreign subsidiaries with large operational footprints.
The company has regulatory approvals and market presence in the United States, multiple European Union countries, and select other international markets. Manufacturing and development activities are primarily U.S.-based, while international sales and marketing are largely executed through partners, giving Senseonics a global footprint without extensive overseas infrastructure.
Leadership & Governance
Senseonics is led by an executive team with experience in medical devices, diagnostics, and regulated healthcare markets. Leadership emphasizes long-term innovation in implantable biosensing technology, disciplined capital management, and partnership-driven commercialization to scale globally.
Key executives include:
- Timothy Goodnow – President and Chief Executive Officer
- Mukul Jain – Chief Operating Officer
- Andrew Weiss – Chief Financial Officer
- Mark A. Schweitzer – Chief Medical Officer
- Sam Shepherd – Executive Vice President, Research and Development
The company is governed by a board of directors with expertise in medical technology, finance, and corporate governance, and operates in compliance with U.S. public company regulatory standards as outlined in its SEC filings.